Send to

Choose Destination
Gynecol Minim Invasive Ther. 2018 Jul-Sep;7(3):114-118. doi: 10.4103/GMIT.GMIT_57_18. Epub 2018 Aug 23.

Effect of Vaginal Estriol Use in Total Laparoscopic Hysterectomy with Gonadotropin-Releasing Hormone Agonist Therapy.

Author information

Department of Gynecology, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan.
Department of Gynecology and Obstetrics, Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa, Japan.


Study Objectives:

The aim of this study is to evaluate the effects of vaginal estriol therapy in total laparoscopic hysterectomy (TLH) with gonadotropin-releasing hormone agonist (GnRH-a) treatment.


Retrospective analysis.

Design Classification:

Canadian Task Force classification II-2.


Department of Gynecology, Yokohama City University Medical Center, Japan.


We retrospectively investigated 50 fibroid cases that had TLH with preoperative GnRH-a treatment and compared the surgical outcome with or without vaginal estriol use (1mg). Estriol was used administered for two weeks before TLH.

Measurements and Main Results:

A total of 12 patients (27%) received vaginal estriol (1 mg) for 14 days before TLH. As a result of vaginal estriol treatment, there were no group differences in uterus size reduction with GnRH-a treatment (22% vs. 15%, P = 0.20), uterine removal time through the vagina (12.5 min vs. 18.5 min, P = 0.18), rate of vaginal dehiscence (3% vs. 0%, P = 0.76) or in the rate of perineal laceration (33% vs. 34%, P = 0.55).


The use of vaginal estriol treatment before TLH with GnRH-a therapy did not improve surgical outcomes.


Estriol; gonadotropin-releasing hormone agonist; laparoscopic hysterectomy

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
Loading ...
Support Center